CytomX Therapeutics (NASDAQ: CTMX)
CytomX Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
CytomX Therapeutics Company Info
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
News & Analysis
Why CytomX Therapeutics Stock Was Skyrocketing This Week
One pundit believes the company might have a winning cancer drug in its pipeline.
CytomX (CTMX) Q2 Revenue Drops 26%
Why CytomX Therapeutics Stock Is Crashing Today
Investors didn't like the company's preliminary phase 2 results for its experimental cancer therapy.
Is This Innovative Cancer Research Biotech a Buy?
Unlike many other cancer-research companies, CytomX is choosing an unconventional approach: turning tumors' high levels of protein activities against themselves. Will it be successful?
Valuation
Earnings Transcripts
CytomX Therapeutics (CTMX) Q2 2022 Earnings Call Transcript
CTMX earnings call for the period ending June 30, 2022.
CytomX Therapeutics (CTMX) Q1 2022 Earnings Call Transcript
CTMX earnings call for the period ending March 31, 2022.
CytomX Therapeutics (CTMX) Q4 2021 Earnings Call Transcript
CTMX earnings call for the period ending December 31, 2021.
CytomX Therapeutics, inc (CTMX) Q3 2021 Earnings Call Transcript
CTMX earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.